News
News
Enrollment of oral powder T-1101 OPC phase trial has completed in Taiwan
T-1101, oral powder for constitution (OPC), from Taivex has completed the phase I trial in Oct, 2019. Total 21 patients have received T-1101 (Tosylate) OPC treatment in 4 clinical trial centers. According to the Phase clinical data, T-1101 has initially proved its safety and efficacy. Taivex will continue the development of T-1101 to further clinical trial with oral capsule form …
T-1301, a multi-targeted anti-cancer developmental drug candidate, is licensed from The National Health Research Institutes to Taivex Therapeutics Corp.
Taivex Therapeutics Corp. (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1301 (formerly, DBPR216), a potential anti-cancer developmental drug candidate, effective on April 8. T-1301 is a novel small molecular multi-target tyrosine kinase inhibitor (TKI), which is orally available and exhibited potent inhibitory efficacy against both wild type and mutant forms of …
Dr. Lun Kelvin Tsou receiving the 14th Tien Te Lee Biomedical Young Scientists Award
Dr. Lun Kelvin Tsou, associate Investigator of IBPR. Dr, Tsou with his team members had development a noval small molecule drug conjugate, DBPR115, that could target a biomarker phosphatidylserine and the deliver the anti-tumor agent to the tumor sites. By increasing the concentration of drug around the tumor, to decrease the side effects. Dr. Tsou was awarded the 14th Tien …
A major milestone for cancer drug development in Taivex! T-1101 OPC initiates Phase I clinical study
T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate Phase I clinical study in Taiwan. Patients with advanced tumors have been enrolled into an ongoing open-label, Phase I dose escalation study in Taiwan. Enrollment for this study in Taiwan started in July 2017. T-1101 …
